STADA Arzneimittel Aktiengesellschaft (SAZ) Given a €82.00 Price Target by Independent Research GmbH Analysts
Independent Research GmbH set a €82.00 ($95.35) price objective on STADA Arzneimittel Aktiengesellschaft (ETR:SAZ) in a research note published on Friday morning. The brokerage currently has a neutral rating on the stock.
SAZ has been the topic of several other research reports. Commerzbank Ag set a €58.00 ($67.44) price objective on STADA Arzneimittel Aktiengesellschaft and gave the stock a sell rating in a research report on Wednesday, August 16th. Warburg Research set a €74.40 ($86.51) target price on STADA Arzneimittel Aktiengesellschaft and gave the company a sell rating in a research note on Tuesday, September 5th. Nord/LB set a €65.53 ($76.20) target price on STADA Arzneimittel Aktiengesellschaft and gave the company a sell rating in a research note on Thursday, August 31st. Finally, S&P Global set a €66.25 ($77.03) target price on STADA Arzneimittel Aktiengesellschaft and gave the company a neutral rating in a research note on Thursday, August 3rd. Four analysts have rated the stock with a sell rating and two have given a hold rating to the company. The company currently has an average rating of Sell and an average target price of €71.43 ($83.06).
STADA Arzneimittel Aktiengesellschaft (ETR SAZ) opened at €81.50 ($94.77) on Friday. STADA Arzneimittel Aktiengesellschaft has a 1 year low of €41.41 ($48.15) and a 1 year high of €84.20 ($97.91).
TRADEMARK VIOLATION WARNING: “STADA Arzneimittel Aktiengesellschaft (SAZ) Given a €82.00 Price Target by Independent Research GmbH Analysts” was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this story on another domain, it was illegally stolen and republished in violation of US & international copyright & trademark laws. The legal version of this story can be read at https://www.thecerbatgem.com/2017/11/14/stada-arzneimittel-aktiengesellschaft-saz-given-a-82-00-price-target-by-independent-research-gmbh-analysts.html.
STADA Arzneimittel Aktiengesellschaft Company Profile
STADA Arzneimittel Aktiengesellschaft engages in the development and marketing of active pharmaceutical ingredients for the health care and pharmaceutical markets worldwide. It operates through two segments, Generics and Branded Products. The Generics segment provides various generic active ingredients, including Tilidine naloxone for pain; Atorvastatin for elevated cholesterol levels; Pantoprazole for stomach ulcer/reflux; Diclofenac for pain/inflammation; and Enalapril for high blood pressure indications.
Receive News & Stock Ratings for STADA Arzneimittel Aktiengesellschaft Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STADA Arzneimittel Aktiengesellschaft and related stocks with our FREE daily email newsletter.